AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AbbVie Inc. Announces Quarterly Dividend of $1.64 per Share
ByAinvest
Friday, Sep 5, 2025 11:04 am ET1min read
AbbVie Inc. declares a quarterly dividend of $1.64 per share. The company specializes in therapeutic drug research and development, with a geographic sales distribution of 76.4% in the US, 2.6% in Germany, and smaller percentages in other countries.
AbbVie Inc. (NYSE: ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to shareholders of record as of October 15, 2025. This latest dividend increase underscores the company's commitment to shareholder value, as it has raised its dividend by 310% since its inception in 2013 [1].AbbVie, a member of the S&P Dividend Aristocrats Index, has consistently increased its dividend for at least 25 consecutive years, reflecting its strong financial performance and stability. The company's mission is to discover and deliver innovative medicines that address serious health issues across key therapeutic areas, including immunology, oncology, neuroscience, and eye care, as well as its Allergan Aesthetics portfolio [1].
In addition to its dividend announcement, AbbVie has been actively expanding its product pipeline. Recently, the company agreed to pay up to $1.2 billion to acquire Gilgamesh's short-acting psychedelic bretisilocin, which is being explored for the treatment of psychiatric diseases, including major depressive disorder (MDD) [2]. This acquisition highlights AbbVie's growing interest in hallucinogenic drugs for mental health conditions.
AbbVie is also making progress with its lymphoma therapy, epcoritamab, in partnership with Genmab. New data from a mid-stage trial suggests that the bispecific antibody can be safely administered in an outpatient setting, potentially improving access to treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [3].
With a geographic sales distribution of 76.4% in the US, 2.6% in Germany, and smaller percentages in other countries, AbbVie continues to focus on its core markets while expanding its global footprint [1].
References:
[1] https://finance.yahoo.com/news/abbvie-declares-quarterly-dividend-130700697.html
[2] https://www.nature.com/articles/d41573-025-00149-0
[3] https://seekingalpha.com/news/4491809-abbvie-updates-data-genmab-partnered-lymphoma-drug
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet